Novo Nordisk Predicts Strong Second Half
Here's our initial take on Novo Nordisk's (NYSE: NVO) fiscal 2025 first-quarter financial report.
Novo Nordisk beat earnings estimates but slightly missed top-line revenue expectations. However, the results throughout its business were quite strong, and management gave an upbeat outlook for the rest of the year -- which was exactly what investors were looking for.
Let's start with the business results. First, note that Novo Nordisk reports its results in Danish kroner (its local currency), and all of these figures are at constant exchange rates.
Source Fool.com
